Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients

Trial Title: Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients

NCT ID: NCT05488587

Condition: Hepatocellular Carcinoma

Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular

Study type: Observational

Overall status: Unknown status

Study design:

Time perspective: Cross-Sectional

Intervention:

Intervention type: Diagnostic Test
Intervention name: magnesium and zinc levels
Description: measuring magnesium and zinc levels
Arm group label: healthy individuals
Arm group label: hepatocellular carcinoma
Arm group label: liver cirrhosis

Summary: Hepatocellular carcinoma (HCC) is the sixth most frequent malignancy worldwide, with an estimated 906,000 new cases and 830,000 deaths in 2020. It is also the third leading cause for cancer deaths, with 15% 5-year survival rate . Diagnosis of HCC in cirrhotic patients is mainly based on non-invasive imaging techniques. Multiphasic computed tomography (CT) and dynamic contrast-enhanced magnetic resonance imaging (MRI) are the most sensitive imaging techniques for diagnosis of HCC. While the most common serologic marker for early screening of HCC is alpha-fetoprotein (AFP) . Liver is the main site of trace elements metabolism, and their levels are affected by different causes of liver disease .

Detailed description: Hepatocellular carcinoma (HCC) is the sixth most frequent malignancy worldwide, with an estimated 906,000 new cases and 830,000 deaths in 2020. It is also the third leading cause for cancer deaths , with 15% 5-year survival rate. Diagnosis of HCC in cirrhotic patients is mainly based on non-invasive imaging techniques. Multiphasic computed tomography (CT) and dynamic contrast-enhanced magnetic resonance imaging (MRI) are the most sensitive imaging techniques for diagnosis of HCC. While the most common serologic marker for early screening of HCC is alpha-fetoprotein (AFP). Liver is the main site of trace elements metabolism, and their levels are affected by different causes of liver disease. Zinc (Zn) is an essential trace element which is required for the function of numerous enzymatic molecules active in human cell metabolic pathways. Zn plays an important role in cell growth, differentiation, apoptosis, and metabolism, with more than 300 proteins that regulate cellular functions containing Zn-binding domains. Zn protects against carcinogenesis as it helps activation of deoxyribonucleic acid (DNA) repair enzymes. Also it is a component of superoxide dismutase, an enzyme that removes free radicals. Zn deficiency was reported to be associated with increased liver fibrosis.and hepatitis C virus (HCV) related HCC. Zn deficiency is also associated with complications related to liver cirrhosis, such as sarcopenia and hepatic encephalopathy. Magnesium (Mg), as a co-factor for up to 600 enzymes, has a fundamental role in many physiological and biochemical functions including cell proliferation, DNA repair and energy metabolism. The available data indicate an opposite role of Mg in the oncology field. Many authors showed that a high content of Mg in the diet is associated with a lower incidence of gastric, colon and breast cancers. However, various data showed that the availability of Mg by cancerous tissues could be involved in the development and/or growth of tumors . A little is known about the significance of Mg in liver disease. A negative association of primary liver cancer with dietary intake of Mg has been demonstrated .

Criteria for eligibility:

Study pop:
Adults of both genders with compensated or decompensated liver cirrhosis with or without HCC.

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - Adults (≥18 years old) of both genders with compensated or decompensated liver cirrhosis with or without HCC. Exclusion Criteria: - Patients who received Zn or Mg supplementation within the previous 3 months. - Non-cirrhotic HCC - Patients with other malignancies. - Pregnant and lactating women.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Locations:

Facility:
Name: Sohag university hospital

Address:
City: Sohag
Country: Egypt

Status: Recruiting

Contact:
Last name: Osama R Elsherif, professor

Start date: August 2022

Completion date: August 2023

Lead sponsor:
Agency: Sohag University
Agency class: Other

Source: Sohag University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05488587